Outlook Therapeutics (OTLK) EBT: 2015-2024
Historic EBT for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$75.4 million.
- Outlook Therapeutics' EBT rose 22.05% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$41.6 million, marking a year-over-year decrease of 9.64%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- Per Outlook Therapeutics' latest filing, its EBT stood at -$75.4 million for FY2024, which was down 27.78% from -$59.0 million recorded in FY2023.
- Over the past 5 years, Outlook Therapeutics' EBT peaked at -$38.5 million during FY2020, and registered a low of -$75.4 million during FY2024.
- Moreover, its 3-year median value for EBT was -$66.0 million (2022), whereas its average is -$66.8 million.
- Per our database at Business Quant, Outlook Therapeutics' EBT crashed by 38.04% in 2021 and then increased by 10.70% in 2023.
- Outlook Therapeutics' EBT (Yearly) stood at -$38.5 million in 2020, then tumbled by 38.04% to -$53.2 million in 2021, then declined by 24.24% to -$66.0 million in 2022, then climbed by 10.70% to -$59.0 million in 2023, then decreased by 27.78% to -$75.4 million in 2024.